Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
Номер патента: AU2021392813A1
Опубликовано: 29-06-2023
Автор(ы): Matthew Brennan, Richard Fisher, Spyridon Papapetropoulos
Принадлежит: Vigil Neuroscience Inc
Опубликовано: 29-06-2023
Автор(ы): Matthew Brennan, Richard Fisher, Spyridon Papapetropoulos
Принадлежит: Vigil Neuroscience Inc
Реферат: The present invention provides a method of treating a disease or disorder caused by and/or associated with ABCD1 dysfunction in a human patient, the method comprising administering to the patient in need thereof an effective amount of a compound that increases the activity of triggering receptor expressed on myeloid cells 2 (TREM2). In some embodiments, compound that increases the activity of TREM2 is an agonist of TREM2. In some embodiments, the agonist of TREM2 is a small molecule agonist of TREM2 or an antibody agonist of TREM2.
Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
Номер патента: CA3203783A1. Автор: Richard Fisher,Spyridon Papapetropoulos,Matthew Brennan. Владелец: Vigil Neuroscience Inc. Дата публикации: 2022-06-09.